Mega Contracts Monitor ($100M+) — March 26, 2026

Three HHS awards totaling $792M provide revenue visibility to 2029 via PATH Study, biotech, and COVID immunogenicity R&D.

$138M obligation with $423M potential underscores set-aside advantages for veteran-owned firms in federal IT.

$832M obligation (78% outlayed) signals reliable DOI spending on unaccompanied children services through 2025.

Long performance periods (2025-2029) expose contracts to funding shifts, with low early outlays in $161M BARDA award.

COVID-19 R&D ($126M) vulnerable to shifting pandemic priorities.

Heavy subcontracting (119 subs at $285M in Acacia; 12 at $27M in Westat) risks delays or disputes.

Unexercised options total ~$700M+ across contracts (e.g., $455M Westat, $285M Acacia, $423M - $138M AATD).

BARDA biotech/COVID R&D awards ($287M combined) signal follow-on potential in health innovation.

45% of value ($792M) in health R&D (NAICS 54171x) via NIH/BARDA, with cost-plus and T&M structures favoring incumbents.

SDVOSB IT ($138M VA) and nonprofit legal/social services ($832M DOI) highlight stable, competition-limited federal streams.

{"entity"=>"Westat, Inc.", "reason"=>"$505M PATH Study with $455M options through 2028 offers highest upside in ongoing health R&D.", "trigger"=>"option funding or outlay acceleration beyond $213M"}

{"entity"=>"PPD Development LP", "reason"=>"$126M COVID R&D to 2029 from BARDA with full options committed.", "trigger"=>"outlay growth past $23M or variant program expansions"}

{"entity"=>"HHS BARDA Programs", "reason"=>"Cluster of $287M awards signals biotech momentum.", "trigger"=>"new $100M+ task orders"}